Establishing Pharmaceutical Intermediates and APIs as Growth Drivers
First written in FY2016. 20 of 37 entries say "Advanced", first in FY2017-Q1. Latest entry: 2026-07-31.
The whole theme swung hardest in 2023: 1 of 7 companies on the "Worse" side.
1 other company's latest entry also says "Worsened".
- 2026-07-31WorsenedEarnings
「Because sales of some active pharmaceutical ingredients and active pharmaceutical ingredient intermediates declined, sales were ¥706 million, a decrease of ¥587 million, or 45.4%, from the same quarter of the previous year.」
Pharmaceutical-related sales declined 45.4% year on year, indicating deterioration in the short-term sales performance of a growth area. - FY2026ReframedAnnual report
「We formulated a three-year medium-term management plan beginning in the fiscal year ending March 2027. Under the basic policy of “Taking on the challenge of a new stage (sustainable growth through increased corporate value),” we are addressing management challenges to achieve new targets and further strengthen our earnings power. ・Expand the CDMO business and pursue technological innovation in the pharmaceutical field」
The previous direction of making pharmaceuticals a growth area was redefined in the new medium-term plan as the specific business initiatives of expanding the CDMO business and pursuing technological innovation. Pharmaceutical-related sales for the fiscal year were ¥4,661 million, down 4.1% year on year. - 2026-05-19AdvancedManagement Planning
「⑤ Expanding the CDMO business and pursuing technological innovation in the pharmaceutical field」
For the pharmaceutical field, the company specified the expansion of its CDMO business, continued growth in the number of contract projects, efforts in areas related to highly potent active pharmaceutical ingredients and regenerative medicine products, and the use of AI and digital technologies as priority measures. - FY2026-H1AdvancedAnnual report
「Although domestic sales declined, steady sales of APIs and other products for export resulted in a 17.6% increase in sales to ¥2,402 million, up ¥359 million from the previous interim accounting period.」
Pharmaceutical-related sales for the interim period increased 17.6% from ¥2,043 million in the same period of the previous year to ¥2,402 million. Strong sales of APIs and other products for export offset the decline in domestic sales, indicating quantitative progress in the growth-driver area. - FY2025-H1AdvancedAnnual report
「Although export sales declined, steady sales of some APIs and other products for the domestic market resulted in a 19.0% increase in sales to ¥2,043 million, up ¥325 million from the previous interim accounting period.」
Pharmaceutical-related sales for the interim period increased 19.0% from ¥1,717 million in the same period of the previous year to ¥2,043 million. Strong sales of some APIs and other products for the domestic market offset the decline in export sales. - FY2024ReframedAnnual report
「Against this backdrop, we formulated a three-year medium-term management plan beginning in the fiscal year ending March 2024. Under the basic policy of “Continuously introducing new products while expanding sales of our core products amid a rapidly changing economic environment, thereby laying the foundation for growth over the next 10 years,” we are addressing management challenges to achieve new targets and further strengthen our earnings power. ・Expand the pharmaceutical contract business」
The previous policy of making pharmaceuticals a growth driver was redefined in the new medium-term plan as the specific business initiative of expanding the pharmaceutical contract business. Meanwhile, pharmaceutical-related sales for the fiscal year were ¥4,245 million, down 4.1% year on year. - FY2024-Q3AdvancedAnnual report
「Although sales of some APIs and API intermediates for the domestic market declined, steady export sales resulted in a 2.1% increase in sales to ¥2,689 million, up ¥54 million from the same quarter of the previous year.」
Pharmaceutical-related sales for the nine months ended December increased 2.1% from ¥2,634 million in the same period of the previous year to ¥2,689 million. Steady export sales offset declines in domestic sales of APIs and API intermediates, indicating progress in the growth-driver area. - FY2024-Q2Pharmaceutical-related sales declined for the six months ended SeptemberAnnual report
「Although export sales were steady, lower domestic sales of some APIs and other products resulted in a 9.8% decline in sales to ¥1,717 million, down ¥185 million from the same quarter of the previous year.」
Pharmaceutical-related sales for the six months ended September fell 9.8% from ¥1,903 million in the same period of the previous year to ¥1,717 million. Although export sales were steady, lower domestic sales of some APIs and other products weighed on overall sales. No change in the policy of positioning pharmaceutical intermediates and APIs as growth drivers was indicated. - FY2024-Q1First-quarter pharmaceutical-related sales declinedAnnual report
「Sales declined 3.6% to ¥864 million, down ¥32 million from the same quarter of the previous year, due to lower sales of some APIs and API intermediates.」
Although no change in the policy of positioning pharmaceutical intermediates and APIs as growth drivers was indicated, first-quarter pharmaceutical-related sales fell 3.6% from ¥896 million in the same period of the previous year to ¥864 million. - FY2023-Q3Pharmaceutical-related sales declined for the nine months ended DecemberAnnual report
「Although sales of APIs for the domestic market increased, lower export sales of some APIs and API intermediates resulted in a 10.2% decline in sales to ¥2,634 million, down ¥297 million from the same period of the previous year.」
Pharmaceutical-related sales for the nine months ended December fell 10.2% from ¥2,932 million in the same period of the previous year to ¥2,634 million. Increased domestic sales of APIs were outweighed by lower export sales of some APIs and API intermediates. - FY2023-Q2AdvancedAnnual report
「Although sales of APIs and API intermediates for export declined, steady sales of APIs and other products for the domestic market resulted in an 11.0% increase in sales to ¥1,903 million, up ¥188 million from the same quarter of the previous year.」
Pharmaceutical-related sales for the six months ended September increased 11.0% from ¥1,715 million in the same period of the previous year to ¥1,903 million. Although exports of APIs and API intermediates declined, steady sales of APIs and other products for the domestic market indicate progress in the growth-driver area. - FY2023-Q1AdvancedAnnual report
「Although sales of API intermediates declined, increased API sales resulted in a 3.7% increase in sales to ¥896 million, up ¥31 million from the same quarter of the previous year.」
First-quarter pharmaceutical-related sales increased 3.7% from ¥865 million in the same period of the previous year to ¥896 million. Increased API sales outweighed the decline in API intermediates, indicating quantitative progress in the growth-driver area. - FY2022AdvancedAnnual report
「Although sales of some APIs for the domestic market declined, increased sales of APIs and API intermediates for export resulted in a 7.6% increase in sales to ¥4,806 million, up ¥341 million from the previous fiscal year.」
Full-year pharmaceutical-related sales increased 7.6% from ¥4,465 million in the previous fiscal year to ¥4,806 million. Increased sales of APIs and API intermediates for export were cited as a driver of progress. - FY2022-Q3AdvancedAnnual report
「Although domestic sales of some APIs declined, increased exports of APIs and API intermediates resulted in a 16.2% increase in sales to ¥2,932 million, up ¥409 million from the same quarter of the previous year.」
Pharmaceutical-related sales for the nine months ended December increased 16.2% from ¥2,522 million in the same period of the previous year to ¥2,932 million. The figures indicate progress driven by expanded exports of APIs and API intermediates. - FY2022-Q2Cumulative second-quarter pharmaceuticals-related sales and sales mix declined sharplyAnnual report
「Although sales of API intermediates increased and new-product sales contributed, lower API sales and other factors resulted in a 23.1% decline in sales to ¥1,715 million, down ¥515 million from the same quarter of the previous year.」
Pharmaceutical-related sales for the six months ended September fell 23.1% from ¥2,230 million in the same period of the previous year to ¥1,715 million, while the segment's share of sales declined from 41.0% to 32.9%. Increased sales of API intermediates and contributions from new products were outweighed by lower API sales and other factors. No change in the policy of positioning pharmaceutical intermediates and APIs as growth drivers was indicated. - FY2022-Q1First-quarter pharmaceutical-related sales declinedAnnual report
「Although exports of pharmaceutical intermediates increased and new-product sales contributed, lower domestic sales of APIs resulted in a 4.3% decline in sales to ¥865 million, down ¥38 million from the same quarter of the previous year.」
Pharmaceutical-related sales fell 4.3% from ¥903 million in the same period of the previous year to ¥865 million. Increased exports of pharmaceutical intermediates and contributions from new products were outweighed by lower domestic sales of APIs. - FY2021AdvancedAnnual report
「Although sales of some generic APIs that had performed strongly in the previous fiscal year declined, strong sales of new-drug APIs and raw-material intermediates, together with contributions from new products, resulted in a 14.6% increase in sales to ¥4,465 million, up ¥567 million from the previous fiscal year.」
Full-year pharmaceutical-related sales increased 14.6% from ¥3,897 million to ¥4,465 million. The disclosure cited strong sales of new-drug APIs and raw-material intermediates and contributions from new-product sales. - FY2021-Q3Pharmaceutical-related sales declined for the nine months ended DecemberAnnual report
「Sales declined 14.1% to ¥2,522 million, down ¥414 million from the same quarter of the previous year, due to a sharp decline in sales of some generic APIs and lower sales of API intermediates and new-drug APIs.」
Pharmaceutical-related sales for the nine months ended December fell 14.1% from ¥2,936 million in the same period of the previous year to ¥2,522 million, while the segment's share of sales declined from 36.7% to 34.1%. No change in the policy of positioning pharmaceutical intermediates and APIs as growth drivers was indicated. - FY2021-Q2AdvancedAnnual report
「Although sales of some generic APIs declined sharply from the same period of the previous year, strong sales of other generic APIs, new-drug APIs and API intermediates resulted in a 20.6% increase in sales to ¥2,230 million, up ¥381 million year on year.」
Pharmaceutical-related sales for the six months ended September increased 20.6% from ¥1,848 million in the same period of the previous year to ¥2,230 million. Despite declines in some generic APIs, strong sales of other generic APIs, new-drug APIs and API intermediates indicate quantitative progress in the growth-driver area. - FY2021-Q1AdvancedAnnual report
「Although sales of some generic APIs declined, sales of new-drug APIs and API intermediates expanded sharply, mainly through exports, resulting in a 16.0% increase in sales to ¥903 million, up ¥124 million from the same quarter of the previous year.」
First-quarter pharmaceutical-related sales increased 16.0% from ¥779 million in the same period of the previous year to ¥903 million. Despite declines in some generic APIs, expanded sales, mainly exports of new-drug APIs and API intermediates, indicate quantitative progress in the growth-driver area. - FY2020AdvancedAnnual report
「Strong sales of existing drugs, generic APIs and new-drug intermediates, mainly in Japan, resulted in a 22.0% increase in sales to ¥3,897 million, up ¥703 million from the previous fiscal year.」
Full-year pharmaceutical-related sales increased 22.0% from ¥3,193 million to ¥3,897 million, indicating concrete progress in the area positioned as a growth driver. - FY2020-Q3AdvancedAnnual report
「Strong domestic sales, particularly of existing drugs and new-drug intermediates, resulted in a sharp increase in sales to ¥2,936 million, up ¥939 million (47.1%) from the same quarter of the previous year.」
Pharmaceutical-related sales for the nine months ended December increased 47.1% from ¥1,996 million in the same period of the previous year to ¥2,936 million, while the segment's share of sales rose from 27.9% to 36.7%. The figures indicate progress in the pharmaceutical-related business positioned as a growth driver. - FY2020-Q2AdvancedAnnual report
「Although exports of some existing drugs declined, strong domestic sales of existing drugs, generic APIs and new-drug intermediates resulted in a sharp increase in sales to ¥1,848 million, up ¥637 million (52.7%) from the same quarter of the previous year.」
Pharmaceutical-related sales for the six months ended September increased 52.7% from ¥1,210 million in the same period of the previous year to ¥1,848 million, indicating substantial quantitative progress in the area positioned as a growth driver. - FY2020-Q1AdvancedAnnual report
「Although exports of some existing drugs declined, strong domestic sales of new-drug intermediates and generic APIs resulted in a sharp increase in sales to ¥779 million, up ¥281 million (56.7%) from the same quarter of the previous year.」
First-quarter pharmaceutical-related sales increased 56.7% from ¥497 million in the same period of the previous year to ¥779 million. The figures indicate progress driven by strong domestic sales of new-drug intermediates and generic APIs. - FY2019Full-year sales are expected to be flat year on year, ending the declineAnnual report
「Although domestic sales of some new-drug intermediates and generic APIs declined, sales of existing drugs increased overseas, leaving sales broadly in line with the previous year at ¥3,193 million.」
Full-year pharmaceutical-related sales were broadly unchanged year on year at ¥3,193 million, marking a shift to flat sales after declines through the previous fiscal year. The company stated that obtaining approval for and commencing full-scale operation of new pharmaceutical facilities would contribute to future performance. - FY2019-Q3Pharmaceutical-related sales declined for the nine months ended DecemberAnnual report
「Sales fell sharply to ¥1,996 million, down ¥178 million (8.2%) from the same quarter of the previous year, due to lower sales of new-drug intermediates and APIs and some generic APIs.」
Pharmaceutical-related sales for the nine months ended December fell 8.2% from ¥2,174 million in the same period of the previous year to ¥1,996 million, while the segment's share of sales declined from 29.3% to 27.9%. No change in the policy of positioning pharmaceutical intermediates and APIs as growth drivers was indicated. - FY2019-Q2Cumulative second-quarter pharmaceuticals-related sales and sales mix declined sharplyAnnual report
「Sales fell sharply to ¥1,210 million, down ¥354 million (22.6%) from the same quarter of the previous year, due to lower exports of new-drug intermediates and lower domestic sales of some existing drugs and generic APIs.」
Pharmaceutical-related sales for the six months ended September fell 22.6% from ¥1,565 million in the same period of the previous year to ¥1,210 million, while the segment's share of sales declined from 30.8% to 25.7%. No change in the policy of positioning pharmaceutical intermediates and APIs as growth drivers was indicated. - FY2019-Q1Pharmaceuticals-related sales and sales mix declined sharply in the first quarterAnnual report
「Because sales of certain active pharmaceutical ingredients for new drugs and generics declined substantially during the period, sales fell to ¥497 million, down ¥303 million, or 37.9%, from the same quarter of the previous year.」
First-quarter pharmaceuticals-related sales declined 37.9% from ¥800 million in the same period of the previous year to ¥497 million, while the sales mix also declined from 32.0% to 22.2%. No change in the policy of positioning pharmaceutical intermediates and active pharmaceutical ingredients as growth drivers is stated. - FY2018Full-year pharmaceuticals-related sales declinedAnnual report
「Sales, primarily exports, declined by ¥421 million, or 11.7%, from the previous fiscal year to ¥3,193 million, due to lower sales of certain generic APIs and new-drug intermediates.」
Although the policy of positioning pharmaceutical intermediates and active pharmaceutical ingredients as growth drivers remains in place, full-year pharmaceuticals-related sales declined from ¥3,615 million in the previous fiscal year to ¥3,193 million. - FY2018-Q3Pharmaceuticals-related sales and sales mix declined in the third quarterAnnual report
「Pharmaceuticals-related 1,517 968 2,486 33.3 1,608 566 2,174 29.3」
Third-quarter cumulative pharmaceutical sales declined from ¥2,486 million in the prior-year period to ¥2,174 million, and the sales mix fell from 33.3% to 29.3%. No change to the policy of positioning pharmaceutical intermediates and APIs as growth drivers was stated. - FY2018-Q2Pharmaceutical sales and sales mix declined in the second quarterAnnual report
「Pharmaceutical sales declined from ¥1,718 million in the prior-year cumulative period to ¥1,565 million, while the sales mix fell from 35.3% to 30.8%. No change to the policy of positioning pharmaceutical intermediates and APIs as growth drivers was stated.」
Pharmaceutical sales declined from ¥1,718 million in the prior-year cumulative period to ¥1,565 million, and the sales mix fell from 35.3% to 30.8%. No change to the policy of positioning pharmaceutical intermediates and APIs as growth drivers was stated. - FY2018-Q1AdvancedAnnual report
「Pharmaceuticals 493 292 785 33.0 623 177 800 32.0」
First-quarter pharmaceuticals-related sales increased from ¥785 million in the same period of the previous year to ¥800 million. The sales mix declined from 33.0% to 32.0%, but sales in the area positioned as a growth driver increased in absolute terms. - FY2017AdvancedAnnual report
「Although sales of some existing pharmaceuticals declined, sales of APIs and intermediates for new drugs expanded steadily, resulting in a substantial increase in sales from the previous fiscal year.」
Pharmaceuticals-related sales increased from ¥2,910 million in the previous fiscal year to ¥3,615 million in the current fiscal year. The expansion in sales of active pharmaceutical ingredients and intermediates for new drugs indicates specific progress in the area positioned as a growth driver. - FY2017-Q3AdvancedAnnual report
「Pharmaceuticals 1,538 572 2,110 26.6 1,517 968 2,486 33.3」
Pharmaceutical sales increased from ¥2,110 million, or 26.6% of sales, in the prior-year period to ¥2,486 million, or 33.3%. The figures show progress in both sales and sales mix for a designated growth-driver area. - FY2017-Q2AdvancedAnnual report
「Pharmaceuticals-related 1,134 364 1,499 27.7 1,185 532 1,718 35.3」
Pharmaceuticals-related sales increased from ¥1,499 million, or 27.7% of sales, in the cumulative same period of the previous year to ¥1,718 million, or 35.3%. Although company-wide sales declined, the figures indicate progress in the area positioned as a growth driver. - FY2017-Q1AdvancedAnnual report
「Pharmaceuticals-related 499 146 646 25.2 493 292 785 33.0」
First-quarter results by product category show pharmaceuticals-related sales increasing from ¥646 million, or 25.2% of sales, in the same period of the previous year to ¥785 million, or 33.0%. Although the Company did not explicitly evaluate this as progress under the Medium-Term Plan, the figures indicate progress in the area positioned as a growth driver. - FY2016First statedAnnual report
「We have focused on various initiatives to make pharmaceutical intermediates and raw materials related to amino acids and chemical products, as well as pharmaceutical products, including generic APIs, our growth drivers and put them on a growth trajectory at an early stage.」
Positions pharmaceutical intermediates and raw materials, including generic APIs, at the center of growth.